Goldman Sachs Reports On 2Q For WLP

Goldman Sachs, following the release of 2Q results, is lowering its price target from $99 to $85 but is maintaining its Neutral rating on WellPoint WLP. In its report, Goldman Sachs writes, “Following 2Q, we lower 2011E EPS to $6.95 from $7.50 to reflect less upside for the year. We also lower our 2012-2013 EPS by $0.40 for each year, to $8.00 and $9.00, respectively. This reflects our modestly lower view of company execution following 2011 headwinds in California. We reduce our 12-month price target to $85 from $99.” WLP closed at $68.70 yesterday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorPrice TargetAnalyst RatingsGoldman SachsHealth CareManaged Health Care
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!